Misplaced Pages

Zavegepant

Clinical data
Trade names	Zavzpret
Other names	BHV-3500
License data	US DailyMed: Zavegepant
Routes of administration	Nasal
Drug class	Calcitonin gene-related peptide receptor antagonist
ATC code	N02CD08 (WHO)
Legal status
Legal status	US: ℞-only
Identifiers
IUPAC name N--1-oxopropan-2-yl]-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide
CAS Number	1337918-83-8 as HCl: 1414976-20-7
PubChem CID	53472683 as HCl: 134819878
DrugBank	DB15688
ChemSpider	30814207
UNII	ODU3ZAZ94J as HCl: 000QCM6HAL
KEGG	D11898 as HCl: D11899
ChEBI	CHEBI:229643
ChEMBL	ChEMBL2397415 as HCl: ChEMBL4650220
CompTox Dashboard (EPA)	DTXSID101352039
Chemical and physical data
Formula	C36H46N8O3
Molar mass	638.817 g·mol
3D model (JSmol)	Interactive image
SMILES CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCN(CC3)C4CCN(CC4)C)NC(=O)N5CCC(CC5)C6=CC7=CC=CC=C7NC6=O
InChI InChI=1S/C36H46N8O3/c1-24-19-25(20-28-23-37-40-33(24)28)21-32(35(46)43-17-15-42(16-18-43)29-9-11-41(2)12-10-29)39-36(47)44-13-7-26(8-14-44)30-22-27-5-3-4-6-31(27)38-34(30)45/h3-6,19-20,22-23,26,29,32H,7-18,21H2,1-2H3,(H,37,40)(H,38,45)(H,39,47)/t32-/m1/s1 Key:JJVAPHYEOZSKJZ-JGCGQSQUSA-N Key:VQDUWCSSPSOSNA-RYWNGCACSA-N

Zavegepant, sold under the brand name Zavzpret, is a medication used for the treatment of migraine. Zavegepant is a calcitonin gene-related peptide receptor antagonist. It is sprayed into the nose. It is sold by Pfizer.

The most common adverse reactions include taste disorders, nausea, nasal discomfort, and vomiting.

Zavegepant was approved for medical use in the United States in March 2023.

Medical uses

Zavegepant is indicated for the acute treatment of migraine with or without aura in adults.

References

1. ^ "Zavzpret- zavegepant spray". DailyMed. 9 March 2023. Retrieved 25 August 2023.
2. "Drug Approval Package: Zavzpret". U.S. Food and Drug Administration (FDA). 3 April 2023. Retrieved 25 August 2023.
3. "Pfizer's Zavzpret (Zavegepant) Migraine Nasal Spray Receives FDA Approval" (Press release). 10 March 2023.
4. Dhillon S (June 2023). "Zavegepant: First Approval". Drugs. 83 (9): 825–831. doi:10.1007/s40265-023-01885-6. PMC 10209931. PMID 37227596.
5. Khan ZZ, Ahmed U, Shahzad F, Ali M, Tousif K, Ahmed U, et al. (July 2023). "Safety and Efficacy of Zavegepant in Treating Migraine: A Systematic Review". Cureus. 15 (7): e41991. doi:10.7759/cureus.41991. PMC 10428082. PMID 37593294.
6. Martirosov AL, Giuliano C, Shupp M, Channey S, Kale-Pradhan PB (October 2023). "Zavegepant Intranasal Spray for Migraines". The Annals of Pharmacotherapy. 58 (8): 827–833. doi:10.1177/10600280231209439. PMID 37897226. S2CID 264543368.

Further reading

• Croop R, Madonia J, Stock DA, Thiry A, Forshaw M, Murphy A, Coric V, Lipton RB (October 2022). "Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial". Headache. 62 (9): 1153–1163. doi:10.1111/head.14389. PMC 9827820. PMID 36239038.
• Noor N, Angelette A, Lawson A, Patel A, Urits I, Viswanath O, et al. (2022). "A Comprehensive Review of Zavegepant as Abortive Treatment for Migraine". Health Psychology Research. 10 (3): 35506. doi:10.52965/001c.35506. PMC 9239361. PMID 35774914.
• Scuteri D, Tarsitano A, Tonin P, Bagetta G, Corasaniti MT (November 2022). "Focus on zavegepant: the first intranasal third-generation gepant". Pain Management. 12 (8): 879–885. doi:10.2217/pmt-2022-0054. PMID 36189708. S2CID 252681912.

External links

• Clinical trial number NCT04571060 for "Randomized Trial in Adult Subjects With Acute Migraines" at ClinicalTrials.gov
• Clinical trial number NCT03872453 for "Acute Treatment Trial in Adult Subjects With Migraines" at ClinicalTrials.gov

• Medicine

This analgesic-related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Antimigraine drugs
• Calcitonin gene-related peptide receptor antagonists
• Drugs developed by Pfizer
• Piperazines
• Piperidines
• Indazoles
• Quinolines
• Ureas
• Analgesic stubs